Skip to main content
Livermore
Livermore
ZHEN

Rubius Therapeutics, Inc.

RUBYDelisted Mar 28, 2023
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001709401

Rubius Therapeutics, Inc. was delisted on Mar 28, 2023; its insiders filed their last Form 4 on Feb 27, 2023; 42 institutions reported holding it in 13F filings for Q4 2022, worth $11.2M in total; no superinvestor held it.

Holders of 5% or more of RUBY

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Rubius Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Rubius Therapeutics, Inc. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

5 Schedule 13D and 13G filings on Rubius Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on RUBY
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 14, 2022Flagship Ventures Fund IV General Partner LLC13G/AOld format–––SEC
Feb 11, 2022Artal International Management S.A.13G/AOld format–––SEC
Feb 9, 2022FMR LLC13G/AOld format–––SEC
Jan 26, 2022Baillie Gifford & Co13G/AOld format–––SEC
Mar 8, 2021Artal International Management S.A.13GOld format–New–SEC
Feb 16, 2021Capital World Investors13G/AOld format–––SEC
Feb 16, 2021Flagship Ventures Fund IV General Partner LLC13G/AOld format–––SEC
Feb 8, 2021FMR LLC13G/AOld format–––SEC
Jan 27, 2021Baillie Gifford & Co13G/AOld format–––SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Rubius Therapeutics, Inc. shares.

No Form 144 notices for Rubius Therapeutics, Inc. are on file.